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Background: Eyes sustaining open globe trauma (OGT) is a group at high risk of severe visual impairment.
Proliferative vitreoretinopathy (PVR) is the commonest cause of retinal redetachment in these eyes and is reported
to occur in up to 45% of cases. Intensive anti-inflammatory agents have been shown to be effective at modifying
experimental PVR and to be well tolerated clinically.
The Adjuncts in Ocular Trauma (AOT) Trial was designed to investigate the benefits of using intensive
anti-inflammatory agents (intravitreal and sub-Tenon’s triamcinolone, oral flurbiprofen and guttae prednisolone
1.0%) perioperatively in patients undergoing vitrectomy surgery following open globe trauma.
Methods/design: Patients requiring posterior vitrectomy surgery following open globe trauma will be randomised
to receive either standard treatment or study treatment. Both groups will receive the standard surgical treatment
appropriate for their eye condition and routine perioperative treatment and care, differing only in the addition of
supplementary adjunctive agents in the treatment group. The investigated primary outcome measure is anatomical
success at 6 months in the absence of internal tamponade.
Discussion: This is the first randomised controlled clinical trial to investigate the use of adjunctive intensive
antiinflammatory agents in patients undergoing vitrectomy following open globe trauma. It will provide evidence
for the role of these adjuncts in this group of patients, as well as provide data to power a definitive study.
EudraCT No: 2007/005138/35Background
The worldwide impact of ocular trauma
Trauma is an important cause of visual impairment and
blindness worldwide and a leading cause of blindness in
young adult males [1]. Currently, it is estimated that al-
most 1 million people in the US live with trauma-related
visual impairment, and 40,000 to 60,000 individuals are* Correspondence: philip.banerjee@moorfields.nhs.uk
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reproduction in any medium, provided the ordiagnosed as new cases of trauma-related blindness each
year [2]. Those patients with open globe injuries lose a
mean 70 days of work [3]. Prevent Blindness America esti-
mated that in 1988 approximately 90,000 disabling eye in-
juries occurred at the workplace, resulting in a total direct
cost of $354,870,000; with indirect cost (lost wages, med-
ical expenses, and insurance administration cost), the sum
reached $709,740,000. When the cost of all non-disabling
eye injuries is included, the total easily exceeds $1 billion.
(Prevent Blindness America Statement on the Scope of
the Eye Injury Problem, Schamburg IL, 1996). Globally itl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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result of ocular trauma, with 2.3 million suffering bilateral
low vision and up to 19 million with unilateral blindness
or low vision [4].
In the UK it is estimated that 5,000 patients per year
sustain eye injuries serious enough to require hospital ad-
mission and of these 250 will be permanently blinded in
the injured eye [5]. Ocular trauma is the commonest cause
of unilateral blindness in the world today and in develop-
ing countries the high incidence of ocular trauma has ex-
tensive socioeconomic costs [4].
It is clear from recent published data that although
vitreoretinal surgical techniques have improved, out-
comes remain unsatisfactory and that the development
of proliferative vitreoretinopathy (PVR) is the leading
cause of this [6-9].Proliferative vitreoretinopathy
Eyes sustaining penetrating or open globe trauma (OGT)
are a group at high risk of severe visual impairment. Ret-
inal detachment is common in these eyes and multiple
surgical interventions are often necessary. PVR is the
commonest cause of recurrent retinal detachment and vis-
ual loss in eyes with open globe trauma. It is estimated to
occur in 10-45% of all OGTs [5-13].
PVR can be considered a wound-healing response in a
specialised tissue. This results in the formation of fibro-
cellular membranes on both surfaces of the detached
retina and the posterior hyaloid face. Contraction of
these membranes results in retinal detachment in post-
trauma eyes or in subsequent failure of surgical reattach-
ment. Despite the improvements in vitreoretinal surgery
over the past 15 years, a significant number of cases fail
to achieve reattachment. The most common cause of
anatomic failure in retinal detachment surgery is the de-
velopment of new or recurrent proliferative vitreoretino-
pathy [14,15].Preclinical and clinical data
The cellular components of PVR peri-retinal membranes
(RPE, glial, inflammatory and fibroblastic cells) proliferate
and may also be contractile; they are thus targets for anti-
proliferative agents. There is a notable inflammatory
component to the PVR process with marked blood-
retinal barrier breakdown and a greater tendency to
intraocular fibrin formation [16]. Macrophages and T
lymphocytes have been identified in PVR membranes
[17] and, although relatively small in number, they may
play an important role in membrane development and
contraction through growth factor production. Thus,
both cellular proliferation and the intraocular inflam-
matory response are realistic targets for adjunctive
treatments in PVR.Steroid treatment can potentially influence both inflam-
matory and proliferative components of PVR. Experimental
work has suggested that the corticosteroid triamcinolone
acetonide can reduce the severity of PVR. In addition, it
has been demonstrated that periocular corticosteroids can
reduce [18,19] the severity of experimental PVR [20]. La-
boratory work has also demonstrated that triamcinolone
appears to have no significant retinal toxicity [21] although
in vitro it may be toxic to proliferating retinal cells.
Investigation of the pathobiology of PVR has demon-
strated a process of fibrocellular proliferation and con-
tractile periretinal membrane formation, which appears
to be due to migrating RPE cells [17]. Recent laboratory
investigations by the senior author have demonstrated
the central role of retinal glial upregulation and Müller
cell process extension in the formation of PVR periret-
inal membranes [22,23], suggesting that adjuncts that
transiently affect free-floating intraocular cells may have
limited effect on the PVR process. Hence, targeting the
retinal glial response may be a more effective method of
modifying the clinical development or recurrence of
PVR. We have subsequently tested the effect of triamci-
nolone on the glial response in experimental retinal de-
tachment and found a significant reduction in Müller
cell proliferation in treated animals [24]. The effect of
triamcinolone on the glial response in experimental
retinal detachment is evidence that clinically, in
addition to their antiinflammatory effect, steroids will
downregulate the intraretinal proliferative response
seen in PVR.
Jonas et al. reported that intravitreal crystalline cortisone
was well tolerated in PVR cases undergoing vitrectomy
[25]. Previous small-scale, uncontrolled clinical studies
of PVR have suggested that systemic prednisolone [26],
infused dexamethasone [27], and intravitreal triamcinolone
[28] may reduce the severity of PVR, although none of
these studies were of sufficient power to provide a defini-
tive answer. An initial pilot study by the senior author has
shown that triamcinolone is well tolerated in PVR cases
undergoing vitrectomy and silicone oil exchange and that a
combination of adjuncts targeting the inflammatory com-
ponent of the PVR process may be a potential treatment to
prevent PVR [29]. A small, prospective, non-comparative
clinical study by Cheema et al. [30] concluded that triamci-
nolone may have some benefit as an adjunct in non-
trauma related established PVR, whereas Ahmadieh et al.
[31] found no additional benefit in surgical outcome. Both
groups concluded that further larger studies were required
to definitively answer the question.
Investigational medicinal products
Triamcinolone acetonide is a hydrophobic long-acting
steroid preparation, which is increasingly being adminis-
tered intraocularly to treat a variety of retinal conditions.
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action and good safety profile. It appears to be effective
in preventing intraocular proliferation and stabilising the
blood-retinal barrier, making it a useful adjunctive treat-
ment for retinal diseases resulting in refractory macular
oedema. It is particularly useful in patients who have iso-
lated ocular disease, especially unilateral, providing an
antiinflammatory and antiproliferative efficacy equal to or
greater than that achieved with systemic administration
while avoiding the unwanted systemic side effects of ster-
oid use. Its effects last about 3 months [32], which covers
the key active developmental stage of PVR that occurs
over about 6 to 8 weeks following ocular injury.
Flurbiprofen is an oral non-steroidal antiinflammatory
drug most commonly used to treat musculoskeletal dis-
orders including rheumatoid disease, osteoarthritis, and
bursitis, but in ophthalmic practice it is commonly used
to treat scleritis. The rationale for its use in this study
stems from evidence suggesting that non-steroidal anti-
inflammatory medications given perioperatively may
limit the degree of blood-retinal barrier breakdown and
have been shown to inhibit cellular proliferation in vitro
[33-35].
Prednisolone acetate 1% is an eye drop suspension
used commonly in the treatment of steroid-responsive
inflammatory conditions of the eye. It remains the
most potent topical steroid treatment licensed for use
in the UK.
Combining corticosteroids and non-steroidal antiin-
flammatories has been shown to have a synergistic effect
in reducing blood-ocular barrier breakdown [33].
Methods/design
This is a phase 2, single-masked, single-centre, pilot, ran-
domised, controlled clinical trial. Forty patients will be
recruited to partake in the study. Participants will be ran-
domised into either the treatment group (additional peri-
operative antiinflammatory adjuncts) or control group (no
additional treatment). Both groups will receive the stand-
ard surgical treatment appropriate for their eye condition
and routine preoperative and postoperative treatment and
care, differing only in the addition of supplementary anti-
inflammatory agents in the treatment group.
Objectives
Primary:
To determine whether adjunctive use of antiinflammatory
agents in eyes requiring vitrectomy following open globe
trauma has an effect on anatomic reapposition of the
remaining retina to the retinal pigment epithelium in the
absence of an internal tamponade agent at 6 months post
surgery. This pilot study aims to provide data to power a
definitive future study.Secondary:
To determine whether adjunctive use of
antiinflammatory agents in eyes requiring vitrectomy
following open globe trauma has an effect on:
(1) Visual acuity at 6 months (ETDRS method)
(2) Number of procedures required to achieve retinal
reattachment
(3) Presence and grade of postoperative proliferative
vitreoretinopathy according to the Retina Society
classification on proliferative vitreoretinopathy (1991)
(4) Persistent submacular fluid found by optical
coherence tomography in the presence of retinal
reattachment
Further secondary objectives include providing infor-
mation regarding the rate of recruitment, case mix of
ocular trauma, and patient loss to follow-up rates.Eligibility
Inclusion criteria
 All patients with an open globe injury requiring
vitrectomy either following open globe trauma
(OGT) or as the primary procedure itself.
(OGT is classified as one of the following: The eyewall
has a full-thickness injury in the form of a rupture
caused by a blunt object, laceration caused by a sharp
object, penetrating/perforating injury caused by a sharp
object, or intraocular foreign body injury.)
In the case of bilateral injury, the worst injured eye (at
the investigator’s discretion) will be included in the study.Exclusion criteria
 Age < 18 or > 80 years of age
 Pre-existing glaucoma
 Previous vitrectomy surgery to the affected eye
 Pregnant or breastfeeding females
 Previous known adverse reaction to any of the IMPs
 Enrolment in other studies
 Inability to attend regular follow-up
 Unable to give informed consent
Patient recruitment will only be done when the trial
has documented REC, Regulatory and Local Trust R&D
approval. The study is conducted in accordance with the
International Conference on Harmonisation for Good
Clinical Practice, as set out in the European Union Clin-
ical Trials Directive (2001) and associated UK Regula-
tions (2004). The study will comply at all times with the
Declaration of Helsinki (2000).
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outpatients and emergency referrals at Moorfields Eye
Hospital. At screening, a structured interview will be con-
ducted by research staff, including questions on coexisting
ocular pathology, previous ophthalmic surgical procedures
and cause of injury, to confirm that all inclusion and ex-
clusion criteria are satisfied.
Patients are then randomised to either the treatment arm
or control arm. An unstratified pre-randomised list of 40
study IDs will be held by the trials pharmacist, and following
informed consent and recruitment into the trial, participants
will be allocated to the lowest unused study ID. Out of
hours (i.e. weekends and bank holidays), the next study ID
in sequence will be kept in a sealed envelope in a secure lo-
cation on site when access to the trials pharmacist is limited.
Baseline assessments will be performed within 2 weeks
prior to the scheduled operation date. Data including pa-
tient demographics; site, nature and extent of ocular in-
jury; and a full slit-lamp ophthalmic examination will be
included. Where posterior chamber assessment is directly
possible, retinal attachment status, presence and grade of
PVR, and spectral domain OCT-guided foveal thickness
and macula volume will be recorded. Where media opa-
city precludes a direct fundal assessment, B scan ultrason-
ography will be used to document retinal attachment
status, and parameters regarding grade of PVR and foveal
thickness and volume will be deemed unrecordable.
Interventions
Treatment group
Preoperative Treatment Guttae prednisolone forte 2
hourly for up to 1 week will replace any topical antiin-
flammatory agents that the patient may already be using,
and all other ocular treatment will be continued
Perioperative Treatment 4 mg/0.1 ml intravitreal
triamcinolone acetonide will be injected into the vitre-
ous cavity following closure of the scleral ports at the
end of the procedure.
40 mg/1 ml triamcinolone acetonide will be given as
a posterior sub-Tenon’s injection prior to suturing the
conjunctiva.
Standard subconjunctival antibiotic injection of 125 mg
cefuroxime will be given.
Postoperative Treatment Guttae prednisolone forte
hourly for 1 week followed by a tapering regimen for 3–
26 weeks thereafter depending on the degree of post-
operative inflammation and cystoid macular oedema.
50 mg flurbiprofen orally bid for 1 week
Routine topical antibiotics (guttae chloramphenicol
0.5% qds for 2 weeks) and mydriatics (guttae cyclopento-
late 1%, frequency and duration at surgeon’s discretion)Control group
Preoperative No additional treatment is given. Patients
are instructed to continue with their current treatment,
which may already include topical antiinflammatory
agents, such as guttae dexamethasone, and topical anti-
biotics and mydriatics.
Perioperative Standard subconjunctival medications to
include 4 mg betamethasone and 125 mg cefuroxime will
be given.
Postoperative Routine topical antibiotics (guttae chlor-
amphenicol 0.5% qds 2 weeks), topical steroids (guttae
dexamethasone 0.1%, frequency and duration at operat-
ing surgeon’s discretion) and topical mydriatics (guttae
cyclopentolate 1%, frequency and duration at operating
surgeon’s discretion) will be given.
Masking
This is a single-masked study to participants only. Al-
though the preoperative and postoperative regimens dif-
fer, participants are not informed to which group they
have been randomised. It is not possible to mask the in-
vestigator, as the primary IMP, intravitreal triamcinolone,
is clearly visible on posterior chamber assessment. The
operating surgeon will be masked to the randomisation
of the participant, until the end of the procedure, to
avoid any bias regarding surgical management.
Study visits and assessment schedule
Postoperative study visits will not differ from the routine
schedule for vitreoretinal procedures at the study site, i.e.
day 1, 10 days, 4–6 weeks, 3 months and 6 months. The
time window allowed around these scheduled visits will be
as follows: day 10 (±3 days), week 4–6 (±7 days), and
months 3 and 6 (±14 days). At each scheduled postopera-
tive study visit, a full ophthalmic assessment will be com-
pleted, to include slit-lamp biomicroscopy (± indirect
binocular ophthalmoscopy when required), and parameters
including ETDRS visual acuity, Goldmann applanation
tonometry, anterior segment assessment and retinal attach-
ment status will be recorded. Spectralis domain optical co-
herence tomography will be used to record central foveal
thickness and total macula volume. (See Figure 1 for an
outline of the study visit and assessment schedule.)
In patients in whom silicone oil is used as a tamponade
agent, its routine removal will not be considered a reo-
peration, and routine subsequent follow-up will be contin-
ued until the patient can return to the study visit schedule.
Other vitreoretinal interventions over the trial period will
be considered reoperations and recorded as such. Post-
operative visits related to reoperations, or any other atten-
dances outside the study visit schedule, will be recorded as
‘unscheduled visits’. CRFs identical in composition to the
Screening- 
-14 to Day 1
Treatment 
Day 1
Day 2 Day 10 
(+/-3
days)






Informed Consent , Data Protection 
Form
X
Medical and Ophthalmic Histories X X
Vital Signs BP/BM/pulse X X
Urinary Pregnancy test X X
ETDRS BCVA X X X X X X
Patient and Primary Repair Assessment 
Form
X
Biomicroscopic Examination SE SE SE SE SE SE
Complete Clinical Trial Preop 
Prescription
X X
IOP SE SE SE SE SE SE SE
OCT SE SE SE SE SE SE
Complete Clinical Trial Per and Post op 
Prescription
X X
Operation Record Form X
Concomittant Medication Form X X X X X X
Adverse Event X X X X X X X
Early Study Withdrawal
Protocol Deviation
SE = study Eye, ETDRS BCVA = ETDRS Best Corrected Visual Acuity, BP = Blood 
Pressure, BM = Blood Monitoring (capillary glucose), IOP = Intraocular Pressure, OCT = 
Optical Coherence Tomography
Figure 1 Outline of the study visit and assessment schedule.
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in the data analysis on completion of the study.
Following the final study visit at 6 months, participants
will be discharged back to the care of their General Prac-
titioner. Participants requiring ongoing ophthalmic care
will continue to be followed up under their admitting
consultant.Outcome Measures
Primary
Successful anatomic reapposition of the remaining retina to
the retinal pigment epithelium in the absence of an internal
tamponade agent at 6 months post-primary vitrectomy
surgery.Secondary
Analysis of the following secondary outcomes at 6 months
post-primary vitrectomy surgery will be performed:
(1) Best corrected visual acuity using the ETDRS
method
(2) Number of procedures required to achieve retinal
reattachment
(3) Presence and grade of postoperative PVR [36]
(4) Persistent submacular fluid found by optical
coherence tomography in the presence of retinal
reattachment.
(5) Recruitment rate
(6) Case mix of ocular trauma
(7) Loss to follow-up rate
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Safety reporting will adhere to the sponsor’s standard oper-
ating procedures, and the trial team is confident that means
are in place to monitor, record and report adverse events in
line with the MHRA guidelines. An external Data Monitor-
ing Committee is in place with an agreed charter to which
to adhere. They will meet 6 to 12 monthly or on an ad hoc
basis as required.
Expected adverse events will include cataract, raised
intraocular pressure, hypotony, sterile hypopyon, retinal
detachment, uveitis and further surgery.
Unexpected adverse events will include endophthalmi-
tis and systemic illness.
Trial size and duration
As this is a pilot study, a power calculation to deter-
mine sample size was not performed. A total of 40
patients was deemed a feasible number over the study
period and expected to provide sufficient data to power
a definitive study.
An internal audit of the incidence of open globe
trauma at the study site provided data estimating an
expected recruitment rate of two cases per month. This
would result in the required sample size achieved in
20 months and completion of the trial in 26 months.
Statistical analyses
The statistical analysis plan will be written in advance of
the data analysis by the trial statistician and will be
approved by the Trial Steering Committee and/or the
Data Monitoring Committee. Data analysis will adhere
to the CONSORT guidelines for randomised controlled
trials. Baseline characteristics of the two groups will be
compared to assess the adequacy of randomisation.
Primary endpoint analysis
The proportion of patients in whom anatomical retinal
attachment remains at 6 months post primary vitrec-
tomy will be reported with 95% confidence intervals.
Secondary endpoint analysis
Summary statistics for all secondary outcomes will be
provided by treatment group, and if statistical compari-
sons are made, results will be reported as exploratory.
Any deviations from the statistical analysis plan will be
described and justified in the final report, as appropriate.
Trial Organisation and monitoring
Trial management committee
David Charteris, Chief Investigator, Moorfields Eye Hospital,
London, UK
Philip Banerjee, Co-Investigator, Moorfields Eye Hospital,
London, UKCatey Bunce, Co-Investigator/Trial Statistician, Moorfields
Eye Hospital, London, UKTrial steering committee
Prof. Roger Hitchings, Chair, Emeritus Prof. of Glaucoma and
Allied Studies University College London and Moorfields Eye
Hospital, London
Hadi Zambarakji, Consultant Ophthalmologist and
Clinical Trialist, Whipps Cross University Hospital NHS
Trust, London
Sue Beer, Lay Person
David Charteris, Chief Investigator, Moorfields Eye
Hospital, London, UK
Philip Banerjee, Co-Investigator, Moorfields Eye Hospital,
London, UK
Catey Bunce, Co-Investigator/Trial Statistician, Moorfields
Eye Hospital, London, UKExternal data monitoring committee
Prof. Robert Maclaren Nuffield, Laboratory of Ophthalmol-
ogy and Oxford Eye Hospital Biomedical Research Centre,
University of Oxford, John Radcliffe Hospital, Oxford, UK
Timothy Jackson, Consultant Vitreoretinal Surgeon
and Clinical Trialist, King’s College, London, UK
Victoria Cornelius, Senior Lecturer in Medical Statis-
tics, King’s College, London, UK
David Broadway, Consultant Ophthalmologist, Glaucoma
Specialist, Norfolk and Norwich University Hospitals NHS
Foundation TrustTrial documentation and data collection
Case report forms will be designed and produced by the
investigators, according to the sponsor’s CRF template.
The final version will be approved by the sponsor. It will
be the responsibility of the investigators to ensure the
accuracy of all data entered onto the CRFs. A delegation
log will identify all trial personnel with responsibilities
for data collection and handling, including those who
have access to the trial database.
Data handling will be performed adhering to the Data
Protection Act 1998.Ethics and competent authority review
Applications to the UK main and Local Research and Ethics
Committee (REC) have received favourable opinions and a
Clinical Trial Authorisation has been issued by the MHRA.Publication policy
The results of this pilot study will be submitted for
publication in peer-reviewed medical journals regard-
less of whether the findings are in favour of the trial
interventions.
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Trial Start - September 2011
Projected Trial End - November 2013
Trial Duration - 24 months
Duration of patient’s participation - 6 months
Discussion
This pilot randomized controlled trial investigating the
use of intensive antiinflammatory agents will be the first
to evaluate their role as an adjunctive agent in patients
undergoing vitrectomy surgery following open globe
trauma. As this group of patients is often given a poor
visual prognosis, largely because of the high incidence of
retinal detachment complicated by PVR, a positive out-
come could potentially have significant implications in
the change of management of these patients.
As this is a pilot study, it is anticipated that the results
will provide sufficient valuable data to assist in powering
a definitive study. As well as providing data regarding
the case mix of ocular trauma at the study site, recruit-
ment rate, and loss to follow-up rates, it aims to evaluate
whether adjunctive antiinflammatory agents offer any
additional benefit in this group of patients. As the sam-
ple size is small and has not been subject to a power cal-
culation, we accept that we may limit our sensitivity to
small differences between the two groups.
We also accept that the cohort of participants is likely
to be quite a heterogeneous group given that open globe
trauma can vary significantly in extent and severity.
However, we expect the adequacy of randomization to
compensate for this and shall acknowledge any unequal
weighting within the groups as limitations of this pilot
study. As the single-centre pilot study serves a wide geo-
graphical catchment area with a broad patient demo-
graphic representative of the UK, we do not expect the
results to provide a misleading estimate of treatment ef-
fect. We would expect this to be confirmed in a defini-
tive multicentre study.
The authors acknowledge the limitations of a single
masked study, but have made every effort to reduce in-
vestigator bias by: (1) masking the operating surgeon to
the treatment allocation until the end of the surgical
procedure and (2) being explicit in definitions of clinical
findings and adverse events and defining rigid manage-
ment protocols, e.g. for IOP rise. The trial team consid-
ered an independent assessor of the primary outcome
measure at 6 months, but felt that there was insufficient
evidence to suggest this to be necessary and added add-
itional cost to a pragmatic exploratory pilot study. Our
projected recruitment rate is based on a retrospective
audit of the incidence of relevant cases at the study
site. We expect a high recruitment uptake following suc-
cessful eligibility screening, due to the poor prognosis
associated with current standard treatment, and areoptimistic that our recruitment target be met within the
projected timescale.
In summary, this is the first randomised controlled
clinical trial to investigate the use of adjunctive intensive
antiinflammatory agents in patients undergoing pars
plana vitrectomy following open globe trauma.
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